ISRG Intuitive Surgical NASDAQ pre-market 28 Jan 2026: AI growth vs 66.80 PE
ISRG stock trades at $525.04 pre-market on 28 Jan 2026, down 0.71% after opening at $532.61. Volume is running near 1,476,425 shares versus an average 1,842,495. Investors are weighing recent product approvals and AI-enabled procedure growth against a rich valuation: PE 66.80 and market cap $188.21B in the United States (NASDAQ). This note focuses on how Intuitive Surgical, Inc. (ISRG) fits an AI stocks strategy and what moves could matter next.
ISRG stock: market snapshot and news drivers
This pre-market session shows ISRG at $525.04, down $3.77 or 0.71% versus yesterday’s close of $528.81. Day range is $523.54–$535.00, year range is $425.00–$609.08, and 50/200-day averages are $561.56 and $516.02 respectively.
Recent headlines include an FDA clearance for the da Vinci 5 in select cardiac procedures and mixed analyst activity. See live coverage at CNBC and a news digest at MarketBeat.
ISRG stock: earnings, fundamentals and growth metrics
Intuitive Surgical reported trailing EPS $7.86 and a TTM PE near 65.44–66.80, signaling high growth expectations priced into the stock. Revenue per share is $28.36, net income per share $8.05, and free cash flow per share $6.40. These metrics support a strong cash position: cash per share $13.83 and no net debt.
Financial growth remains positive: FY 2024 revenue growth 17.24%, operating cash flow grew 33.15%, and free cash flow jumped 73.93% year-over-year. The business mixes recurring instrument and services revenue with platform sales, which underpins margin durability in the healthcare sector.
ISRG stock: AI-led opportunity and commercial catalysts
Intuitive’s platform expansion — da Vinci surgical systems plus the Ion endoluminal system — ties directly to AI-enhanced workflow, imaging, and outcomes data. Early adoption of AI-driven guidance in procedures could lift procedure volumes and attach rates for instruments and services. Analyst mix (Buy 17, Hold 4, Sell 2) reflects confidence in the market opportunity but varied timing expectations.
For AI stocks investors, ISRG’s product cycle and regulatory wins are the core catalysts. Commercial execution, hospital buying cycles, and reimbursement remain timing risks that will decide near-term returns.
ISRG stock: valuation, technicals and Meyka grade
Valuation is rich on standard multiples: price/sales 18.76, price/book 11.04, and EV/EBITDA ~50.57. Profitability is strong: gross margin 66.06%, operating margin 29.27%, and net margin 28.38%.
Meyka AI rates ISRG with a score out of 100: 74.70 | Grade B+ | Suggestion BUY. This grade factors in S&P 500 comparison, sector and industry peers, financial growth, key metrics, analyst consensus, and forecasts. Technical indicators show RSI 65.69 (near bullish), MACD histogram modestly positive, and ATR 11.47 pointing to moderate intraday volatility. These data support a buy bias for investors focused on AI-enabled surgical growth, while cautioning on the premium valuation.
ISRG stock: risks, downside and key catalysts to watch
Primary risks include slower capital spending by hospitals, competitive moves from other robotics players, and any regulatory setbacks for new procedures. High valuation leaves limited margin for execution misses: a small revenue shortfall could translate into meaningful price pressure given the PE ~66.80.
Watch next earnings announcement (calendar: 2026-04-21) for guidance updates, procedure volume trends, instrument attach rates, and any commentary on AI/analytics adoption. Big catalysts that could re-rate the stock include faster-than-expected system placements and stronger recurring revenue growth.
ISRG stock: practical strategy and trading notes for AI stocks portfolios
For investors using an AI stocks strategy, consider position sizing to reflect ISRG’s premium multiples and healthcare exposure. A phased buy on weakness toward the 200-day average $516.02 and area of stronger support near the $500.00 round level can limit timing risk. Traders may use RSI and MACD crossovers for shorter holds; longer-term investors should focus on procedure growth and system install cadence.
Meyka AI provides real-time signals and alternative data to monitor adoption trends; reference our ISRG coverage on Meyka AI for live updates.
Final Thoughts
Key takeaways: ISRG stock trades at $525.04 pre-market on 28 Jan 2026 with a mixed near-term tape and strong long-term fundamentals tied to AI-enabled procedural growth. The shares carry a premium valuation—PE 66.80, price/sales 18.76—that requires above-trend execution to justify current levels. Meyka AI’s forecast model projects a 12‑month level near $605.93, implying an upside of 15.40% from today’s price $525.04. Meyka AI rates ISRG with a score out of 100: 74.70 (Grade B+, Suggestion BUY). Forecasts are model-based projections and not guarantees. Investors focusing on AI stocks should weigh Intuitive Surgical’s durable cash generation and AI-related product catalysts against valuation and hospital buying cycle risks before deciding size and timing.
FAQs
What is the current ISRG stock price and pre-market change?
ISRG stock is at $525.04 pre-market on 28 Jan 2026, down $3.77 or 0.71% from the prior close of $528.81. Volume sits near 1,476,425 shares.
How does Meyka AI view ISRG stock?
Meyka AI rates ISRG with a score out of 100: 74.70, Grade B+, with a BUY suggestion. The grade factors in benchmarks, sector performance, growth, metrics, and analyst consensus.
What is the ISRG stock forecast and implied upside?
Meyka AI’s forecast model projects a 12-month price near $605.93, implying an upside of 15.40% versus the current $525.04. Forecasts are model-based projections and not guarantees.
What key risks should ISRG investors watch?
Key risks for ISRG stock are slower hospital capital spending, competitive robotics advances, and execution gaps on system installs or recurring revenue. High valuation raises downside sensitivity to misses.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
